Pfizer Japan's R&D centre reborn as RaQualia
This article was originally published in Scrip
Some 18 months after announcing that it would close the facility, Pfizerhas spun out its former central research laboratories in Japan into a new stand-alone business which will develop and license a portfolio of compounds sourced from its former parent.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.